[PSMA radioligand therapy-State of the art].

Radioligand therapy (RLT) using [177Lu]Lu-PSMA-617 represents an innovative approach for treating metastatic castration-resistant prostate cancer (mCRPC). This therapy employs radioactively labeled ligands that specifically bind to prostate-specific membrane antigen (PSMA), allowing targeted radiation directly to tumor cells. Following its approval by the European Medicines Agency (EMA), the VISION trial demonstrated significant improvements in survival rates and quality of life for patients compared to traditional therapies. Numerous clinical studies are currently underway to evaluate the effectiveness of [177Lu]Lu-PSMA-617 in combination with other treatments and across various disease stages. Despite these advancements, there remains a critical need for further research on optimal dosing, application and patient selection to enhance therapeutic outcomes and explore new treatment avenues.